Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18214727 | 0.80 | CA12 (0.31) | CA12CA1CA2CA9LRRK2 | |
| SCHEMBL5985190 | 0.77 | PDK2 (0.34) | CA12CA1CA2CA9LRRK2 | |
| SCHEMBL26833958 | 0.77 | KMT2A (0.30) | KMT2A | |
| SCHEMBL2619433 | 0.74 | PIK3CG (0.41) | CDK2PIK3CG | |
| SCHEMBL1979674 | 0.72 | CDK2 (0.45) | CDK2L3MBTL1PIK3CG | |
| SCHEMBL18647269 | 0.72 | CDK2 (0.34) | CDK2 | |
| SCHEMBL21720481 | 0.72 | CDK2 (0.34) | CDK2 | |
| SCHEMBL21720208 | 0.72 | CDK2 (0.34) | CDK2L3MBTL1 | |
| SCHEMBL9963871 | 0.72 | CDK2 (0.34) | CDK2MEN1KMT2AL3MBTL1 | |
| SCHEMBL14112956 | 0.72 | CDK2 (0.34) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-7335653-B2 | Chemokine receptor antagonists; CCR9-mediated disorders such as inflammatory and autoimmune diseases | CHEMOCENTRYX, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7297797-B2 | Pyrrolines | BAYER CROPSCIENCE AG (DE) | 2007-11-20 | — | — | US | disclosed |
| US-7297797-B2 | Pyrrolines | BAYER CROPSCIENCE AG (DE) | 2007-11-20 | — | — | US | disclosed |
| US-7282513-B2 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20070203131-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CDK2 4475/4885MEN1 3647/4885KMT2A 4789/4885 |
| US-20080176912-A1 | GPR40 AGONISTS | GPR119, GPR65, GPR55 | CDK2 4589/4885MEN1 3863/4885KMT2A 3666/4885 |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | CDK2 12/4885MEN1 76/4885KMT2A 1168/4885 |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | CDK2 291/4885MEN1 2171/4885KMT2A 1631/4885 |
| US-20070203131-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | CDK2 1231/4885MEN1 4818/4885KMT2A 4477/4885 |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | RIPK1, RIPK2, RIPK4 | CDK2 981/4885MEN1 2726/4885KMT2A 3837/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | CDK2 3936/4885MEN1 641/4885KMT2A 4507/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | CDK2 1533/4885MEN1 4870/4885KMT2A 2610/4885 |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | CDK2 1061/4885MEN1 3626/4885KMT2A 3554/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | CDK2 4027/4885MEN1 641/4885KMT2A 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.